Epitranscriptomic Therapies Market By Therapeutic Approach (Small-Molecule Inhibitors, RNA Editing and Engineered RNA Modulation), By Target Class (RNA Writers, RNA Erasers, RNA Readers, RNA Editing Enzymes), By RNA Modification (m6A Modification, m5C Modification, m1A Modification, Pseudouridine Modification, A-to-I RNA Editing, Other RNA Modifications), By Indication (Oncology, Infectious Diseases, Neurological Disorders, Metabolic and Other Diseases), By Development Stage (Preclinical, Clinical), By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Epitranscriptomic Therapies Market: Clinical Validation of RNA Modification Creates a New Precision-Medicine Category

The Global Epitranscriptomic Therapies Market was valued at an estimated USD 0.92 billion in 2025 and is projected to reach USD 3.49 billion by 2032, expanding at a CAGR of 21.0% during 2026–2032.

 

Epitranscriptomics refers to the study and therapeutic targeting of chemical modifications on RNA molecules that regulate how genetic information is expressed without altering the underlying DNA sequence, and the market encompasses drugs and technologies designed to modulate these RNA modifications for disease treatment.The strongest clinical activity currently centers on N6-methyladenosine (m6A), particularly inhibition of the METTL3 RNA methyltransferase, while programmable RNA-editing technologies are extending the opportunity into inherited diseases.

 

The market includes several emerging approaches: small-molecule inhibitors of RNA-modifying enzymes, oligonucleotide-based RNA editing, antisense approaches that alter RNA structure or processing, and engineered systems capable of adding or removing modifications at selected RNA sites. FDA-approved RNA-targeting mechanisms of action, including antisense oligonucleotides and siRNA-based therapeutics, have already validated the clinical viability of RNA-level modulation, supporting the translational pathway for these approaches. Modified mRNA chemistry also contributes technology and manufacturing knowledge to the sector, although established mRNA vaccine revenue should not be counted as direct epitranscriptomic therapy revenue.

 

METTL3 Is Establishing the First Clinical Market for Epitranscriptomic Drugs

METTL3 has become the leading therapeutic target because it controls m6A deposition on messenger RNA and is implicated in several processes relevant to cancer, including malignant-cell survival, differentiation, treatment resistance and immune regulation. The availability of orally active METTL3 inhibitors has also given developers a conventional small-molecule route into an otherwise novel area of RNA biology.

STORM Therapeutics' STC-15 is currently the most advanced direct epitranscriptomic therapy. The company describes STC-15 as the first inhibitor of an RNA-modifying enzyme to enter human clinical development, and the candidate is now being evaluated in Phase 2 in selected sarcomas.

Clinical data presented at ASCO 2026 provided one of the field's strongest human efficacy signals. In the reported sarcoma subset, STC-15 produced a 54% disease-control rate at 12 weeks. These results are important because they move METTL3 inhibition beyond laboratory target validation and demonstrate measurable antitumor activity in patients.

STC-15 has consequently moved into a Phase 1b/2 program that evaluates the compound both as monotherapy in selected relapsed sarcomas and in combination with the PD-1 inhibitor toripalimab in advanced solid tumors. ClinicalTrials.gov lists the study as recruiting, with an estimated enrollment of 107 participants and Phase 2 monotherapy cohorts focused on dedifferentiated liposarcoma and leiomyosarcoma.

The commercial importance of this program goes beyond sarcoma. A positive monotherapy result could establish METTL3 inhibition in a defined oncology niche, while successful combinations with checkpoint inhibitors would expose the mechanism to much larger cancer populations. Combination development is therefore likely to become an important competitive area as companies seek to position RNA-modification therapies alongside established oncology treatments rather than as standalone experimental agents.

STORM reinforced this strategy in April 2026 with a USD 56 million Series C financing, alongside dosing of the first patient in its Phase 2 sarcoma trial. The financing is significant for an emerging therapeutic category because capital is now being directed toward clinical expansion rather than only target discovery and preclinical validation.

 

Sarcoma Provides an Early Proof Market, but the Larger Opportunity Is in Common Solid Tumors

Sarcoma offers a useful early clinical setting because several advanced subtypes have limited treatment alternatives and defined histological groups can be studied separately. The National Cancer Institute's SEER program estimates 13,910 new soft-tissue cancer cases and 5,400 deaths in the United States in 2026. These figures represent the broader disease burden and should not be interpreted as the number of patients eligible for METTL3 treatment.

The larger revenue opportunity would come from expansion into cancers such as lung, pancreatic, ovarian, endometrial and head-and-neck tumors. STC-15's combination study already extends development beyond sarcoma, while EPICS is evaluating METTL3 biology across several advanced solid tumors.

This creates an important commercial test for the drug class. METTL3 inhibitors will need to show that RNA modification provides incremental benefit in tumors already treated with checkpoint inhibitors, targeted drugs, chemotherapy, radiation or antibody-drug conjugates. Success in a broad indication would substantially increase the value of METTL3 platforms, while weaker results could leave the market concentrated in biomarker-selected or rare tumor populations.

 

EP102 Adds Direct Competition to the METTL3 Drug Class

EPICS Therapeutics is developing EP102, an oral METTL3 inhibitor currently in a Phase 1 first-in-human study for advanced solid tumors. ClinicalTrials.gov lists the program as recruiting and estimates enrollment of 48 patients, with safety, maximum tolerated dose, pharmacokinetics, pharmacodynamics and preliminary antitumor activity among the principal study objectives.

EPICS originally announced that the European program had authorization across as many as 12 hospitals in five countries and could include up to 78 patients under its broader development plan. Current company information states that multiple treatment cohorts have begun and that clinical safety and pharmacokinetic data are expected during 2026.

EP102 gives the market an important independent test of METTL3. STC-15 proving clinical activity alone would validate one molecule; activity from multiple chemically distinct inhibitors would provide stronger evidence that METTL3 itself represents a reproducible drug class.

EPICS has positioned EP102 primarily around cancers where METTL3 dysregulation intersects with DNA-damage response pathways. The company has generated preclinical evidence in pancreatic, lung and other tumor models and is evaluating combination strategies involving radiation and established cancer therapies. In April 2026, EPICS reported preclinical pancreatic cancer data showing dose-dependent tumor-growth inhibition and stronger activity when EP102 was combined with radiation.

Medicinal-chemistry work published by EPICS in 2026 describes the optimization of its earlier compounds into orally available EP102, including improved pharmacokinetic properties and activity across solid and hematological tumor models. This raises the competitive standard for METTL3 programs: potency alone will not be sufficient, as oral exposure, selectivity, tolerability, dosing convenience and combination potential will influence differentiation.

 

Competitive Landscape: Clinical Stage, Target Breadth and Biomarker Control Define Positioning

Competition in the epitranscriptomic therapies market remains concentrated because only a small number of companies have translated RNA-modification biology into clinical-stage therapeutics. The field can currently be separated into direct RNA-modifying enzyme developers, programmable RNA-editing companies, and broader RNA-modifying protein platforms.

STORM Therapeutics — First-Mover Advantage in Direct RNA Modification

STORM Therapeutics holds the leading position in direct epitranscriptomic drug development, with STC-15 becoming the first RNA-modifying enzyme inhibitor to enter clinical trials and now advancing into Phase 2, giving the company the most extensive human clinical dataset among METTL3-targeting competitors. Beyond its clinical lead, STORM is evaluating both monotherapy and PD-1 combination strategies, has recently secured additional funding to support Phase 2 expansion, and is strengthening its precision-medicine approach through a collaboration with Alida Biosciences. This partnership leverages EpiPlex and EpiScout sequencing platforms to measure m6A RNA modifications in patient samples and assess whether baseline epitranscriptomic signatures can predict treatment response, potentially enabling patient stratification, improved trial design, and a stronger position in future precision-oncology applications.

 

EPICS Therapeutics — Emerging Challenger with Solid-Tumor Focus

EPICS Therapeutics is the most direct competitor to STORM in the METTL3 space, developing the oral inhibitor EP102 with a strategy focused on solid tumors linked to DNA-damage biology rather than sarcoma, supported by a multi-country European Phase 1 program that enables broader clinical expansion. Its competitive positioning will depend on demonstrating a favorable therapeutic window and meaningful activity across common solid tumors, with preclinical pancreatic cancer data and radiation-combination studies offering a distinct development path compared with STC-15’s sarcoma and immunotherapy-combination focus, making the parallel clinical progression of both drugs one of the first head-to-head benchmarks for METTL3 inhibition.

 

Wave Life Sciences — Clinical Validation of Programmable RNA Editing

Wave Life Sciences is advancing an adjacent RNA-editing approach through its AIMer platform, where WVE-006 uses an oligonucleotide to recruit endogenous ADAR enzymes to correct disease-causing RNA in alpha-1 antitrypsin deficiency rather than targeting m6A enzymes. In May 2026 clinical data, WVE-006 demonstrated meaningful protein restoration, including up to ~70% reduction in mutant Z-AAT and increased functional AAT levels across both biweekly and monthly dosing regimens, supporting proof that endogenous RNA-editing can generate therapeutic protein changes in humans. While not a direct METTL3 competitor, these results validate the broader feasibility of RNA-editing therapeutics and may strengthen investor confidence in reversible transcript-based medicine.

 

Accent Therapeutics and AstraZeneca — Broader RNA-Modifying Protein Competition

Accent Therapeutics has played a foundational role in advancing commercial interest in RNA-modifying proteins and continues to operate through strategic partnerships, including collaborations with AstraZeneca and Boehringer Ingelheim focused on oncology drug discovery. While its current lead clinical program, ATX-295, targets KIF18A rather than a direct epitranscriptomic enzyme, its broader pipeline explores RNA-associated targets such as DHX9 and XRN1, positioning the company as an adjacent rather than direct METTL3 competitor. Overall, its partnerships with major pharmaceutical companies highlight a broader industry trend in which RNA biology is increasingly being developed through collaborations and asset deals between biotech innovators and large pharma rather than by standalone specialist companies.

 

Evotec and AlidaBio Strengthen the Supporting Competitive Ecosystem

Evotec contributes drug-discovery and IND-enabling capabilities, including high-throughput transcriptomics and mRNA-modulation screening that can evaluate thousands of compounds with transcript-level analysis to support candidate selection. In parallel, AlidaBio provides specialized RNA-modification measurement technologies, and its collaboration with STORM highlights the growing role of epitranscriptomic assay companies in enabling clinical development through target engagement quantification and biomarker discovery. Together, these capabilities indicate that competition in the epitranscriptomic therapies market is expanding into an integrated ecosystem spanning drug developers, sequencing and assay providers, chemistry platforms, and clinical-development partners rather than being limited to therapeutic molecules alone.

 

Biomarker Development Is Becoming a Competitive Requirement

RNA modifications introduce a more complex biomarker landscape than fixed DNA mutations because they are dynamic and can vary across transcripts, tissues, cellular states, and treatment conditions. As a result, developers must establish robust assays that confirm both target engagement and downstream pathway modulation. STORM Therapeutics’ collaboration with AlidaBio exemplifies this approach, using transcript-specific m6A profiling in patients treated with STC-15 to correlate molecular changes with clinical outcomes. If successful, such biomarker strategies could reshape the market by enabling patient stratification, improving trial efficiency through enriched populations, and supporting companion diagnostic development. This would also create a parallel market for epitranscriptomic sequencing and modification-specific assays, where companies integrating therapeutics with validated biomarker platforms may gain a competitive advantage over those relying solely on traditional tumor classification methods.

 

FTO and Other RNA-Modifying Enzymes Provide Longer-Term Pipeline Expansion

METTL3 currently dominates clinical development, but other RNA-modification regulators such as FTO, ALKBH5 and related enzymes remain active research targets due to their roles in cancer-cell survival, differentiation, immune signaling and treatment resistance, creating additional opportunities for new drug classes. However, the field faces a key challenge in target specificity, as some compounds initially labeled as FTO inhibitors have later shown off-target activity against unrelated proteins, complicating interpretation of antitumor effects. As a result, development standards are rising, with future candidates expected to demonstrate clear biochemical selectivity, human pharmacodynamic validation, and transcript-level confirmation of target engagement, while preclinical tumor inhibition alone is becoming insufficient to establish competitive value.

 

RNA Editing Expands the Market Beyond Oncology

Programmable RNA editing is expanding epitranscriptomic medicine beyond oncology into rare genetic diseases, liver and metabolic disorders, and potentially broader chronic conditions, with ADAR-based systems offering a key advantage by leveraging endogenous human enzymes rather than permanent genomic modification. The most advanced clinical validation comes from Wave Life Sciences’ WVE-006, which has demonstrated the ability to restore wild-type protein in patients, providing the first human proof of reversible transcript correction, while the company continues to advance additional RNA-editing programs that could enable multi-disease applicability. Unlike small-molecule METTL3 inhibitors that can address broad patient populations sharing a common enzymatic dependency, RNA-editing oligonucleotides require highly sequence-specific design, specialized manufacturing, and efficient tissue delivery, making them more personalized but also more technically complex to scale.

 

Regulation Is Becoming More Defined for Oligonucleotide and Individualized RNA Therapies

Regulatory clarity is gradually improving as more oligonucleotide drugs enter development. FDA's final 2024 guidance for oligonucleotide therapeutics addresses clinical-pharmacology issues including organ impairment, QT assessment, immunogenicity and drug interactions. The guidance also notes that certain RNA/DNA editing mechanisms fall outside its standard scope, meaning early interaction with individual FDA review divisions remains important for newer editing technologies.

FDA also issued draft guidance in 2024 covering nonclinical safety assessment of oligonucleotide-based therapeutics, reflecting the need for modality-specific evaluation rather than simply applying conventional small-molecule requirements.

A major development followed in February 2026, when FDA introduced its draft Plausible Mechanism Framework for individualized therapies targeting ultra-rare genetic diseases. The framework is designed to help developers establish evidence of safety and effectiveness when conventional large clinical studies may not be feasible.

This framework is more relevant to mutation-specific RNA editing and individualized oligonucleotides than to broad oncology drugs such as METTL3 inhibitors. However, it reduces regulatory uncertainty for one of the fastest-emerging areas of programmable RNA medicine.

Europe is also establishing more detailed expectations around oligonucleotide development and manufacturing. EMA guidance addresses manufacturing processes, characterization, specifications, analytical controls and conjugation of synthetic oligonucleotides.

 

North America and Europe Lead Clinical Translation

North America is a major center for the clinical and regulatory development of epitranscriptomic and RNA-editing therapies (accounting for ~50% market share, valued at approximately USD 0.46 billion in 2025, and projected to grow at a CAGR of 21.0%). STC-15 is recruiting through U.S. oncology centers, Wave is advancing clinical RNA-editing programs, and FDA is developing more specific regulatory frameworks for oligonucleotide and individualized genetic therapies.

Europe has built a strong position in direct RNA epigenetics, accounting for an estimated ~35% share of the global epitranscriptomic therapies market, with a 2025 regional market size of approximately USD 0.32 billion and a projected CAGR of ~20.5% (2026–2032), closely tracking global growth trends. STORM Therapeutics originated in Cambridge, UK, while Belgian company EPICS Therapeutics is conducting EP102 development through a multicountry European clinical network.

Asia-Pacific remains important for basic RNA-modification research, medicinal chemistry, computational screening and disease-model development, accounting for approximately 25% of the global epitranscriptomic therapies market, valued at around USD 0.23 billion in 2025, and is projected to grow at a CAGR of ~20% during the forecast period. However, direct clinical-stage METTL3 programs reviewed in the current landscape remain concentrated primarily in the United States and Europe.

 

Financing Is Moving from Platform Science Toward Clinical Evidence

Capital formation in the sector is becoming increasingly milestone-oriented. Early epitranscriptomic companies were financed largely around novel target discovery and the possibility of opening previously inaccessible RNA biology. Recent investment is increasingly connected to measurable clinical progress.

STORM's USD 56 million Series C coincided with its transition into Phase 2 sarcoma development. EPICS previously secured financing alongside progression of EP102 and stated that its available resources were intended to carry the program toward key clinical endpoints.

Partnerships are also broadening the funding model. STORM's collaboration with Coherus gives its METTL3 program access to a PD-1 combination strategy, while AlidaBio contributes specialized biomarker capabilities. Accent's alliances with AstraZeneca and Boehringer Ingelheim show that larger pharmaceutical companies are willing to access RNA-related targets through collaboration and asset transactions.

The result is a market moving away from platform novelty as the primary measure of value. Clinical response, target engagement, biomarker reproducibility, combination efficacy and therapeutic selectivity are becoming more important in determining financing and strategic interest.

 

Analyst Perspective: Clinical Reproducibility Will Decide the Size of the Opportunity

The epitranscriptomic therapies market has reached an important development stage. STC-15 has established human clinical activity for METTL3 inhibition and moved into Phase 2. EP102 provides an independent clinical competitor against the same target. WVE-006 has demonstrated therapeutic RNA editing in humans, while assay and sequencing companies are beginning to build infrastructure around direct measurement of RNA modifications.

The next major market milestone is reproducibility. STC-15 must confirm activity in larger and more clearly defined sarcoma populations. EP102 needs to establish human pharmacodynamic activity, tolerability and preliminary efficacy. Combination programs must show whether METTL3 inhibition can improve results from established oncology treatments rather than only produce independent biological activity.

Competition will also expand beyond METTL3 if other RNA writers, erasers and readers produce equally convincing clinical evidence. Target selectivity will be particularly important because the commercial value of a new epitranscriptomic class depends on proving that therapeutic effects come from the intended RNA-modification mechanism.

Near-term opportunity is therefore concentrated in oncology, rare genetic diseases and RNA-editing applications, where molecular targets and clinical endpoints can be defined clearly. Longer-term expansion could extend into metabolic, inflammatory, neurological and other chronic diseases as delivery, biomarkers and target validation improve.

STORM Therapeutics currently holds the first-mover position in direct RNA-modifying enzyme therapeutics, EPICS Therapeutics is creating the first meaningful same-target competition, and Wave Life Sciences provides the strongest clinical validation for programmable endogenous RNA editing. Accent Therapeutics, AstraZeneca, Evotec and specialized epitranscriptomic technology companies broaden the competitive environment around RNA-target discovery, drug development and molecular measurement.

As clinical datasets increase, competitive advantage is likely to concentrate around companies that can combine selective drug chemistry, measurable RNA target engagement, predictive biomarkers and reproducible clinical benefit. Those capabilities will determine whether epitranscriptomic therapies remain a specialized experimental field or develop into a broader precision-medicine drug category.

 

Epitranscriptomic Therapies Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 0.92 Billion
Revenue Forecast in 2032	USD 3.49 Billion
Overall Growth Rate	CAGR of 21.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Therapeutic Approach, By Target Class, By RNA Modification, By Indication, By Development Stage, By Geography
By Therapeutic Approach	Small-Molecule Inhibitors, RNA Editing and Engineered RNA Modulation
By Target Class	RNA Writers, RNA Erasers, RNA Readers, RNA Editing Enzymes
By RNA Modification	m6A Modification, m5C Modification, m1A Modification, Pseudouridine Modification, A-to-I RNA Editing, Other RNA Modifications
By Indication	Oncology, Infectious Diseases, Neurological Disorders, Metabolic and Other Diseases
By Development Stage	Preclinical, Clinical
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Advancing clinical validation of METTL3 inhibitors, growing adoption of programmable RNA editing technologies, increasing investment in precision medicine platforms, expansion of RNA-based therapeutic development beyond oncology
Customization Option	Available upon request